Trial design and participants
This was a phase III, single-center, randomized, two-arm, parallel-group, double-blind, placebo-controlled study, consisting of a screening phase (days -14 to -1) and a 4-week double-blind, placebo-controlled treatment phase. The details of the trial design can be found in the previously published protocol paper [The study design is illustrated in Additional file Epicardial and perirenal adipose tissue thickness (cm): placebo group (A–C) and dapagliflozin group (All participants were screened for all applicable inclusion and exclusion criteria, underwent baseline assessments, and were enrolled during the screening phase. Participants were randomly assigned in a 1:1 ratio to receive dapagliflozin (10 mg, orally, once daily) or placebo for 4 weeks. Randomization and packaging of medicine were handled by the hospital pharmacy. All baseline assessments were repeated at the end of treatment (4 weeks).